Asia-Pacific

The strongest regional dynamic is a widening split between formal access frameworks and actual clinical capacity. Australia remains the reference point because it already permits specialist psychiatrists to prescribe MDMA for PTSD and psilocybine for treatment-resistant depression under the TGA Authorised Prescriber scheme, but the system is visibly becoming more operationally exacting, not looser. In 2026, the TGA published outcomes from its targeted consultation on AP scheme requirements, signalling pressure for clearer expectations around psychiatrist authorisation, on-site supervision, therapist involvement, and product quality standards. That matters regionally because Australia is still the main policy comparator for nearby regulators and clinicians, yet the current motion is about tightening the scaffolding around a rarefied access model, not scaling broad use. The country is also the only one in this group where a live prescribing pathway exists for both MDMA and psilocybin, so every refinement has outsized regional significance.

A second cross-cutting dynamic is the emergence of conditional, practitioner-led pathways that stop short of general market authorisation. New Zealand’s July 2025 Medsafe guidance gives practitioners a route to seek approval to prescribe psychedelics, such as psilocybin, for a defined clinical purpose outside a research setting. That is a real procedural change, and it distinguishes New Zealand from Japan, South Korea and China, but it should not be over-read as liberalisation. Medsafe still describes these substances as needing approval before supply, and the country’s broader controlled-drug framework remains in place. In regional terms, New Zealand is moving towards a named-practitioner, case-by-case model that resembles a regulatory pressure valve rather than an open therapeutic pathway. Blossom also continues to treat esketamine as the clearest approved psychiatric comparator in New Zealand, which reinforces the point that the near-term market is still ketamine-adjacent, not classical-psychedelic.

A third dynamic is that the most visible research activity is clustering around depression, especially treatment-resistant depression, while other indications remain secondary. Australia’s current regulatory language and prescribing guidance centre on PTSD and TRD, and the TGA’s consultation materials make clear that the practical debate is about how to manage therapy-heavy depression care safely. New Zealand’s visible classical-psychedelic work, as described in the country context, sits around LSD microdosing, psilocybin pilots, and ketamine models for depression. Japan’s registered research activity is likewise clinically narrow, with the clearest public signals in TRD, ketamine, psilocybin and esketamine studies. South Korea’s Blossom-linked trials also point towards TRD and MDD rather than broader experimentation. Taken together, the region is not seeing a broadening of indication breadth, it is seeing repeated concentration around affective disorders, especially where rapid-acting or psychotherapy-linked approaches can be tested within existing medical systems.

A fourth pattern is that the region’s regulatory centre of gravity remains fragmented, but the fragmentation is informative. Australia and New Zealand now both have explicit practitioner-facing pathways, yet they differ in maturity and scope: Australia has a live AP prescribing system, while New Zealand has a Medsafe approval route that still sits inside a restrictive medicines regime. Japan and South Korea remain closer to research-only access, with strong central control and no evidence of routine patient pathways for classical psychedelics. Mainland China is even more restrictive in the classical-psychedelic space, but it is not static: ketamine and esketamine remain the visible clinical lane, including supervised hospital use and research around depression and rapid-treatment settings. The result is a region in which “psychedelic medicine” is not one policy model, but at least four: limited prescribing in Australia, case-by-case practitioner approval in New Zealand, research-only or near-research-only in Japan and South Korea, and strict controlled-medicine use in China.

A fifth, quieter dynamic is that the region’s visible investment signal is still regulatory and institutional rather than commercial. Australia’s TGA consultation and pharmacy quality-standard work show that regulators are still trying to define product handling, compounding, and supervision norms. New Zealand’s recent Medsafe guidance and clinical-trial administration materials suggest the same institutional emphasis. In Japan and South Korea, the most meaningful near-term changes are likely to come from trial results, protocol amendments, or hospital-level practice refinement, not from headline policy shifts. India remains a blank page in Blossom, which is itself a cross-cutting signal: the region’s second-most populous country is not yet contributing visible trial or policy momentum in the database, so any future Asia-Pacific commercial thesis will still depend on Australia, New Zealand, Japan, South Korea and China for the near-term evidential base.

Blossom tracks 6 South Korea-linked trials, but the regional picture is more telling than the count itself: the trials are concentrated, the compounds are narrow, and the access story is still highly local. This makes Asia-Pacific a region of regulatory experimentation at the margins, with Australia and New Zealand slowly formalising narrow clinical routes, while Japan, South Korea and China remain anchored to controlled, specialist, or research-only use. The net effect is that the region is producing more procedural clarity than access expansion.

Over the next 12 to 24 months, Asia-Pacific is likely to remain a region of controlled expansion, not liberalisation. Australia is the most likely source of the next meaningful regulatory adjustment, but the direction of travel appears administrative and clinical, not permissive. The TGA’s consultation outcomes suggest that prescriber qualifications, on-site supervision, therapist participation, product quality, and reporting obligations will remain central. That should improve clarity for existing providers, but it also raises the execution bar, which may constrain the pace of clinical scaling. For investors and operators, Australia’s opportunity is therefore less about a sudden rise in patient volume and more about whether the system becomes operationally legible enough to support repeatable specialist care.

New Zealand is the next jurisdiction to watch for translation from guidance into practice. Medsafe’s approval pathway for psychedelic-assisted therapy creates a route that could, in principle, support carefully selected cases outside formal trials. The key question is whether any local practitioners test that route in a visible way, and whether Medsafe’s broader medicinal-product reforms make the approval environment more predictable. The most plausible near-term outcome is a small number of highly documented cases or pilots, not a broad policy move.

Japan and South Korea are more likely to move through data than regulation. Both countries show clinical interest in ketamine, esketamine and, to a lesser extent, psilocybin, but their systems still privilege controlled research and specialist use. Any change in the next year or two is more likely to come from study readouts, protocol extensions or hospital adoption of ketamine-adjacent interventions than from formal psychedelic access reform. Mainland China will probably continue to privilege hospital-based ketamine and esketamine, with research proceeding within a tightly managed pharmaceutical framework. India, unless Blossom coverage improves materially, will remain analytically opaque for this cycle. Overall, the region’s near-term story is one of regulatory clarification without broad access, and research concentration without major compound diversification.